3D Printing (Additive Manufacturing) in Pharmaceutical Drug Delivery: Technologies, Materials, Applications, and Future Perspectives

5. FORMULATION STRATEGIES

5.1 Drug-Loaded Filament Preparation (FDM)

Drug-loaded filaments for FDM are commonly prepared by hot-melt extrusion, in which drug and thermoplastic polymer are blended under heat and shear to form a homogeneous, printable filament of consistent diameter, directly linking pharmaceutical HME expertise to FDM-based printing.^7,8

5.2 Photopolymer-Drug Ink Formulation (SLA)

The drug must be dispersed or dissolved within a photocurable resin system while preserving both printability (viscosity, cure depth) and drug stability under UV/visible light exposure.^7,8

5.3 Powder-Drug Blend Preparation (SLS / Binder Jetting)

Drug and excipient powders are blended to achieve uniform distribution and appropriate particle size/flow for either laser sintering (SLS) or selective binder deposition (binder jetting), as exemplified by the ZipDose powder-liquid platform.^4,5,7,8

5.4 Paste/Gel Formulation (SSE)

Drug is incorporated into a semi-solid hydrogel or paste vehicle with rheological properties (yield stress, viscosity recovery) tuned for extrusion through a fine nozzle while retaining shape post-deposition.^2,3

5.5 Solubility and Stability Considerations

Across all techniques, formulation scientists must reconcile drug solubility/stability with the physical and thermal/photochemical demands of the chosen printing process—thermal stability for FDM, photostability for SLA, sintering-temperature stability for SLS, and aqueous stability for binder jetting and SSE.^7,8

6. DESIGN AND PROCESS PARAMETERS

6.1 CAD Design and Dosage Form Architecture

Infill density, internal channel/lattice structures, geometry (surface-area-to-volume ratio), and shell thickness are primary design levers used to program drug release behavior directly into the printed object.^1,2,3

6.2 Critical Process Parameters by Technology

TABLE 3. REPRESENTATIVE CRITICAL PROCESS PARAMETERS BY 3D PRINTING TECHNOLOGY.^7,8

6.3 Software and Slicing Considerations

Slicing software converts the CAD model into machine instructions and governs layer resolution, print orientation, and support-structure generation, all of which influence final dosage-form mechanical integrity and drug-release behavior.^1,2

7. APPLICATIONS IN DRUG DELIVERY

7.1 Personalized/Precision Dosing

3D printing allows dose and, where relevant, shape/geometry to be adjusted per patient without new tooling, directly supporting precision-dosing needs in narrow-therapeutic-index drugs and individualized titration regimens.^2,3,9

7.2 Polypills and Multi-Drug, Multi-Layer Dosage Forms

Multi-material and multi-nozzle printers have been used to fabricate polypills incorporating several APIs with independently controlled, compartmentalized release profiles within a single printed unit—a natural extension of bilayer tablet principles into a higher-complexity, digitally customizable format.^10,11

AI-assisted design approaches have specifically been applied to multi-layer, multi-drug capsule/tablet architectures to predict and control release profiles for personalized medicine.¹¹

7.3 Pediatric and Geriatric-Friendly Formulations

Printed dosage forms can be engineered with reduced size, altered disintegration behavior, or flavored/shaped presentations, and Spritam itself was specifically designed to address swallowing difficulty through its rapidly disintegrating porous ZipDose matrix—a challenge reported by 40–50% of U.S. adults for conventional tablets and capsules.^4,5,6

7.4 Orphan and Low-Volume Drug Manufacturing

The absence of dedicated compression tooling requirements makes 3D printing economically attractive for small-batch or orphan-drug production runs relative to conventional large-scale tableting infrastructure.^2,3

7.5 Modified-Release Systems via Printed Geometry

Immediate, sustained, pulsatile, and delayed-release behavior can be engineered directly through printed geometry (e.g., shell thickness, core-shell architecture, infill density) in addition to, or instead of, conventional excipient-based release control, as demonstrated in container-tablet designs for multi-drug self-nanoemulsifying delivery systems.¹

7.6 Implants and Drug-Eluting Devices

Beyond oral dosage forms, additive manufacturing has been applied to patient-specific implants and drug-eluting medical devices, leveraging the same digital-design-to-fabrication workflow used for oral solids.^1,2

8. REGULATORY MILESTONE AND CASE STUDY: SPRITAM®

In August 2015, the U.S. FDA approved Spritam (levetiracetam), developed by Aprecia Pharmaceuticals, as the first 3D-printed prescription drug product to reach the market, indicated as adjunctive therapy for partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and children with epilepsy.^4,5,6

Spritam is manufactured using Aprecia's proprietary ZipDose Technology, a binder-jetting-based platform originally developed at the Massachusetts Institute of Technology, which combines formulation science with 3D printing to produce a highly porous tablet matrix capable of incorporating a high drug load—up to 1,000 mg in a single dose—while disintegrating rapidly in the mouth with just a sip of liquid.^4,5,6

This directly addressed a recognized clinical need: difficulty swallowing conventional tablets and capsules, reported by an estimated 40–50% of U.S. adults.⁶

8.1 Lessons from the Spritam Approval Pathway

• Demonstrated that a 3D-printed solid oral dosage form could meet the same quality, safety, and efficacy standards as conventionally manufactured products under existing FDA regulatory pathways, without requiring an entirely new regulatory category.^4,5
• Established binder jetting as a commercially viable, GMP-scalable pharmaceutical 3D printing technology, manufactured in a regulated commercial-scale facility.⁶
• Signaled that high drug-load, rapidly disintegrating architectures—difficult to achieve with conventional compression—represent a clear differentiated value proposition for pharmaceutical 3D printing, rather than novelty alone.^4,5,6

9. EVALUATION PARAMETERS FOR 3D-PRINTED DOSAGE FORMS

• Dimensional accuracy and weight uniformity—verifying that the printed object matches the CAD-specified dimensions and target dose.^1,2
• Mechanical strength/hardness—particularly important for porous binder-jetted or SLS structures, which can be more fragile than compressed tablets.^4,5
• Drug content and content uniformity—critical where multiple drugs are deposited in spatially distinct regions of a multi-material print.^10,11
• Disintegration and dissolution testing—assessing both overall release rate and, where geometry-programmed release is used, correlation with the designed infill/shell architecture.^1,3
• Microstructural characterization—scanning electron microscopy (SEM) and X-ray micro-computed tomography (micro-CT) to visualize internal porosity, layer adhesion, and printed architecture.^7,8
• Drug–polymer compatibility—FTIR, DSC, and XRD studies to confirm absence of degradation or unwanted interaction introduced by thermal (FDM/SLS), photochemical (SLA), or aqueous (binder jetting) processing.^7,8
• Stability studies—accelerated and long-term testing appropriate to the specific printed matrix's moisture sensitivity and porosity.^7,8

10. CHALLENGES IN PHARMACEUTICAL 3D PRINTING

• Scale-up and throughput limitations: most pharmaceutical 3D printers are optimized for small-batch or unit-dose production, and translating this to commercial-volume throughput remains a significant engineering challenge relative to high-speed rotary tablet presses.^1,2,3
• GMP compliance and quality control of printed batches: ensuring batch-to-batch and even unit-to-unit consistency in a technology designed around customization requires new quality control paradigms distinct from traditional batch-uniformity testing.^1,2
• Printer/hardware variability and reproducibility: differences between printer models, nozzle wear, and calibration drift can affect dose accuracy and release behavior over time.^7,8
• Limited excipient/polymer library qualified for pharmaceutical printing: comparatively few polymers and excipients have established pharmaceutical-grade printability data relative to the large excipient library available for conventional tableting.^7,8
• Regulatory framework gaps: existing batch-release and validation paradigms were designed for homogeneous, large-batch conventional manufacturing and require adaptation for a technology capable of producing individualized, single-unit doses.^1,2
• Cost considerations: equipment, qualified materials, and per-unit production costs can exceed conventional tableting for standard (non-personalized) dose strengths, limiting near-term applicability to cases where personalization or complex architecture provides clear clinical value.^1,2,3

11. QUALITY BY DESIGN (QbD) IN 3D-PRINTED FORMULATIONS

As with bilayer and other complex oral dosage forms, a systematic, risk-based QbD approach is increasingly applied to 3D-printed formulation development to build quality into the printed product by design.^1,2

11.1 CQAs, CMAs, and CPPs Specific to Additive Manufacturing

Print-specific CQAs include dimensional accuracy, drug content uniformity across the printed object, mechanical integrity, and release-profile conformity to the designed geometry. CMAs include filament/resin/powder material properties (viscosity, particle size, thermal behavior), while CPPs are technology-specific as outlined in Table 3 (Section 6.2).^7,8

11.2 DoE Approaches for Print-Parameter Optimization

Design of Experiments methodology—mapping the relationship between CPPs (e.g., nozzle temperature and print speed for FDM, or laser power and scan speed for SLS) and CQAs (e.g., dissolution profile, hardness)—supports construction of a validated design space for a given printed dosage form, mirroring the DoE approach already established for bilayer and other complex tablet systems.

11.3 PAT and In-Line Monitoring

Process analytical technology integrated directly into the print process (e.g., in-line imaging or spectroscopic monitoring of each printed layer) is an emerging area of interest for real-time verification of dose and structural conformity during fabrication, extending the PAT concepts already used in bilayer tablet manufacture to a layer-by-layer printed context.

12. ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING INTEGRATION

AI/ML approaches have begun to be applied directly to the design of multi-layer, multi-drug 3D-printed dosage forms, using predictive models to guide material selection, infill geometry, and print parameters toward a target controlled-release profile, rather than relying solely on iterative trial-and-error formulation development.¹¹

Such AI-driven design of customized multi-layer architectures illustrates how machine learning can compress the design-space exploration process for complex, personalized-medicine-oriented printed dosage forms.¹¹

Looking forward, digital twin models—virtual, continuously updated representations of the physical print process—and closed-loop print optimization, in which real-time in-line monitoring data feeds back into AI-adjusted process parameters, represent a natural extension of this integration as pharmaceutical 3D printing matures toward routine clinical and point-of-care use.

13. REGULATORY AND INTELLECTUAL PROPERTY LANDSCAPE

13.1 Regulatory Guidance

The Spritam approval demonstrated that 3D-printed pharmaceuticals can be evaluated under existing FDA drug-approval pathways rather than requiring an entirely new regulatory category, though agencies continue to develop more specific guidance addressing the unique quality-control and batch-definition questions raised by additive manufacturing, particularly for point-of-care or decentralized printing scenarios.^4,5

13.2 Point-of-Care/Hospital Pharmacy Printing

The prospect of printing patient-specific doses at the point of care (e.g., hospital or specialty pharmacy) raises distinct regulatory questions regarding who is accountable for quality assurance of the final printed unit—the device/software manufacturer, the material supplier, or the printing site—an area of active regulatory policy development.^1,2

13.3 Intellectual Property Landscape

Patent activity spans both the printer/device level (e.g., Aprecia's proprietary ZipDose Technology platform) and the formulation level (drug-polymer systems optimized for specific print technologies), reflecting the continued commercial value of proprietary pharmaceutical AM platforms.^4,5,6

14. FUTURE PERSPECTIVES

14.1 Point-of-Care and Decentralized Manufacturing

Compact, qualified pharmaceutical 3D printers located in hospital or specialty pharmacies could enable on-demand fabrication of patient-specific doses at the point of care, reducing dependence on centralized large-batch manufacturing for personalized therapy.^1,2,3

14.2 Personalized Polypills for Chronic Disease Management

Multi-material printing of compartmentalized, multi-drug polypills—extending the IR/SR bilayer concept to a fully individualized, multi-API format—is positioned as a key application for chronic, multi-drug disease management, reducing pill burden while enabling patient-specific dose ratios.^10,11

14.3 4D Printing (Stimuli-Responsive Printed Dosage Forms)

4D printing extends 3D-printed structures with materials engineered to change shape or release behavior in response to a physiological stimulus (e.g., pH, temperature, moisture) after fabrication, representing an active frontier explored alongside FDM, SLS, and SLA platforms using stimuli-responsive polymer systems.⁷

14.4 Integration with Digital Health and Telemedicine

Coupling patient-specific prescribing data (from telemedicine or electronic health records) directly to print-file generation could, in principle, close the loop between individualized dose determination and on-demand fabrication, though this remains a largely prospective direction requiring further regulatory and technical development.^1,2

14.5 Sustainable/Green Additive Manufacturing

Reduced material waste relative to subtractive or blend-based conventional manufacturing, and the potential for solvent-free processing routes (e.g., FDM, SLS), position pharmaceutical 3D printing as a potentially more sustainable manufacturing paradigm, meriting further life-cycle assessment as the technology scales.^7,8

15. CONCLUSION

Three-dimensional printing has progressed from a research curiosity to a clinically validated pharmaceutical manufacturing platform, anchored by the 2015 FDA approval of Spritam and its ZipDose binder-jetting technology. Across FDM, SLA/DLP, SLS, binder jetting, and semi-solid extrusion, pharmaceutical 3D printing offers a fundamentally different value proposition from conventional tableting: the ability to engineer dose, geometry, and release profile digitally and individually, rather than through fixed-batch formulation and tooling. Realizing this potential at scale requires continued progress on throughput, GMP-compatible quality control, expansion of the qualified pharmaceutical materials library, and regulatory frameworks suited to individualized manufacturing—challenges increasingly being addressed through QbD-based development and AI-assisted print-parameter optimization. As these barriers are addressed, pharmaceutical 3D printing is well positioned to become a cornerstone technology for personalized medicine, point-of-care manufacturing, and next-generation multi-drug dosage form design.

ACKNOWLEDGEMENT

The author gratefully acknowledges the Department of Pharmaceutics, KMCH College of Pharmacy, Dr. M.G.R. Educational and Research Institute, Chennai, for the facilities and support provided during the preparation of this review.

CONFLICT OF INTEREST

The author declares no conflict of interest.

REFERENCES

1. Kulkarni VR, Kazi M, Shahba AA-W, Radhanpuri A and Maniruzzaman M: Three-dimensional printing of a container tablet: a new paradigm for multi-drug-containing bioactive self-nanoemulsifying drug-delivery systems (Bio-SNEDDSs). Pharmaceutics 2022; 14(5):1082.
2. Michael B, Jayaprakash N, Munivel N and Jaisankar D: 3D printing in drug delivery: emerging technologies, clinical translation, and the future of personalized medicine. Medicine in Drug Discovery 2025; 100242.
3. Kapoor DU, Pareek A, Uniyal P, Prajapati BG, Thanawuth K and Sriamornsak P: Innovative applications of 3D printing in personalized medicine and complex drug delivery systems. iScience 2025; 28(10):113505.
4. FDA approves first 3D-printed drug product. Pharmaceutical Technology. Available from: https://www.pharmtech.com/view/fda-approves-first-3d-printed-drug-product
5. First 3D-printed pill. Nature Biotechnology 2015; 33:1014.
6. 3D-printed drugs: what does the future hold? American Society of Mechanical Engineers (ASME). Available from: https://www.asme.org/topics-resources/content/3dprinteddrugs-does-future-hold
7. Kafle A, Luis E, Silwal R, Pan HM, Shrestha PL and Bastola AK: 3D/4D printing of polymers: fused deposition modelling (FDM), selective laser sintering (SLS), and stereolithography (SLA). Polymers 2021; 13(18):3101.
8. Deshmane S, Kendre P, Mahajan H and Jain S: Stereolithography 3D printing technology in pharmaceuticals: a review. Drug Development and Industrial Pharmacy 2021; 47(9):1362-1372.
9. First FDA-approved medicine manufactured using 3D printing technology now available. PR Newswire/Aprecia Pharmaceuticals. Available from: https://www.prnewswire.com/news-releases/first-fda-approved-medicine-manufactured-using-3d-printing-technology-now-available-300239402.html
10. Keerikkadu M, Chennamsetty S, Shetty A, Tippavajhala VK and Rathnanand M: 3D-printed polypills for personalized medicine and precision oral drug delivery in pharmaceutical practice: a review. International Journal of Pharmaceutics: X 2025; 10:100474.
11. Hu J, Wan J, Xi J, Shi W and Qian H: AI-driven design of customized 3D-printed multilayer capsules with controlled drug release profiles for personalized medicine. International Journal of Pharmaceutics 2024; 656:124114.